Introduction

History

Interest in pancreatic hormones began at the turn of the 20th century. In 1902, Bayliss and Starling discover a pancreatic secretin involved in regulation of water homeostasis, giving rise to interest in pancreatic hormones. Shortly after, in 1906, Moore et al. hypothesize involvement of gastrointestinal hormone extracts in maintenance of the endocrine pancreas. Jean La Barre purifies glucose-lowering gut extracts in 1929 and characterizes them as incretins, which is short for intestine secretion insulin. Finally, in 1984, gastric inhibitory peptide (GIP) is isolated from porcupine intestine. Although GIP was initially characterized for its gastric inhibitory effects (hence the name), it was also shown that the polypeptide played an integral role in insulin signaling and secretion. Interestingly, it was found that the effect of GIP on insulin levels was still seen in its absence, hinting toward the presence of an additional incretin, which has now been classified as glucagon-like peptide-1 (GLP-1).

Biological Role

Figure 1. The biological roles of GIP and and GLP-1, incretin hormones.

General Structure

The Receptor and G Protein (GIPR)

appears as a typical G-Protein Coupled Receptor, containing a with seven helical passes and an , where the ligand binds. These two domains comprise the . Intracellularly, the receptor is bound to a G-Protein which is comprised by the , , and subunits, where the Beta and Gamma subunits typically dimerize. Upon binding of GIP to the receptor, the intracellular signaling cascade is initiated.

Glucose-dependent Insulinotropic Polypeptide

The binds to its receptor extracellularly, inserting itself N-terminus down into the transmembrane and extracellular domains of the GIP receptor. The polypeptide is 42 residues in length and forms a helical structure.

Active Site

A crucial binding interaction within the active site occurs between and receptor residues W296 and Q224. The hydroxyl of the tyrosine residue forms a hydrogen bond to the amide of the glutamine, and the aromaticity of both the tyrosine and tryptophan residues results in pi stacking between them. In GIP agonist diabetes medications, conservation of the Tyr1 residue can determine the drug’s efficacy in initiating a GIP-like response.

Associated Diseases

Medical Relevance

Tirzepatide

Figure 2. Sequence alignment of GLP-1, GIP, and Tirzepatide. Residues shown in black are found in all three amino acid sequences. Pink or red coloration denotes residues that are unique to GIP or GLP-1, respectively. The sequence of tirzepatide is colored accordingly, and residues differing from both GIP and GLP-1 are highlighted in blue. Residues that differ across all three structures are boxed.